Cite

HARVARD Citation

    Chambers, J. et al. (2019). A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab. Clinical oncology. 31 (7), pp. e106-. [Online]. 
  
Back to record